Core Insights - Traws Pharma announced promising clinical efficacy data for rigosertib, showing an overall response rate of 80% and complete responses in 50% of evaluable patients with RDEB-associated SCC [1][2][4] - Rigosertib is being positioned as a potential treatment for cutaneous SCC in RDEB patients, addressing a significant unmet medical need [2][4] - The company is actively seeking partners for the development and commercialization of rigosertib [3][9] Group 1: Clinical Data - The publication in the British Journal of Dermatology marks the first clinical trial of any experimental cancer therapeutic in RDEB-associated SCC [1] - The aggressive nature of RDEB-associated SCC results in a cumulative risk of death of 70% by age 45 and 78.7% by age 55 [4] Group 2: Company Strategy - Traws Pharma is committed to finding a partner to advance rigosertib towards approval [3] - The company is also developing antiviral agents targeting various viral diseases, indicating a broader therapeutic focus [8]